Company profile: Mithra Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of women's health care products focused on contraception, fertility, and menopause. Pipeline centers on an Estetrol (E4) platform with lead development candidates Estelle, a fifth-generation oral contraceptive, and Donesta, a next-generation hormone therapy for menopausal symptoms. Portfolio also includes the Myring contraceptive vaginal ring, Tibelia for menopause, and Zoreline biodegradable implants for hormone-dependent cancers.
Products and services
- Estelle: A fifth-generation combined oral contraceptive pill that prevents pregnancy using 15 mg Estetrol (E4) plus 3 mg Drospirenone
- Donesta: A next-generation hormone therapy in development based on Estetrol (E4) for treating major menopausal symptoms in women
- Estetrol-based platform: A research-grade platform focused on developing products based on Estetrol (E4), a unique estrogen with various potential therapeutic applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mithra Pharmaceuticals
Vistin Pharma
HQ: Norway
Website
- Description: Provider of active pharmaceuticals and solid dosage forms focused on metformin, manufacturing and supplying metformin in various forms, including Metformin Hydrochloride (API) meeting purity and flow quality standards and Metformin Direct Compressible Premix for immediate-release tablet compression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vistin Pharma company profile →
WIL Research
HQ: United States
Website
- Description: Provider of global Contract Research Organization (CRO) services, offering discovery support services, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry, and formulation services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WIL Research company profile →
Uquifa
HQ: Spain
Website
- Description: Provider of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and custom synthesis services for the pharmaceutical industry. Operates three cGMP manufacturing sites (two in Spain, one in Mexico) inspected and approved by major pharmaceutical companies and regulatory authorities, including the US FDA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Uquifa company profile →
ADVI Health
HQ: United States
Website
- Description: Provider of boutique health care advisory services, including market access and pricing strategy; federal and state policy monitoring and modeling; strategic analytics, value and economics; coding and reimbursement for Medicare, Medicaid, VA-DOD, and private payers; and data-driven financial services due diligence to quantify risks, opportunities, and trends.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADVI Health company profile →
Bolder BioPath
HQ: United States
Website
- Description: Provider of pharmacology and pathology services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bolder BioPath company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mithra Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mithra Pharmaceuticals
2.2 - Growth funds investing in similar companies to Mithra Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mithra Pharmaceuticals
4.2 - Public trading comparable groups for Mithra Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →